After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …

Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been
induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare …

During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory
syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people …

The coronavirus spike glycoprotein attaches to host receptors and mediates viral fusion.
Using a broad screening approach, we isolated seven monoclonal antibodies (mAbs) that …

Background Whether a broadly neutralizing antibody (bnAb) can be used to prevent human
immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk …

Attempts to reduce the human immunodeficiency virus type 1 (HIV-1) reservoir and induce
antiretroviral therapy (ART)-free virologic control have largely been unsuccessful. In this …

Inducing antiretroviral therapy (ART)-free virological control is a critical step toward a human
immunodeficiency virus type 1 (HIV-1) cure. In this phase 2a, placebo-controlled, double …

Immunological memory is required for protection against repeated infections and is the basis
of all effective vaccines. Antibodies produced by memory B cells play an essential role in …

INTRODUCTION Immunoglobulin A (IgA) is the most abundant mammalian antibody
isotype, constituting more than 80% of all antibody-secreting plasma cells at steady state …